Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

University of California Davis Cancer Center, Sacramento, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Sacramento, CA
Treatments:ChemotherapyHospital:University of California Davis Cancer Center
Drugs:Journal:Link
Date:May 2010

Description:

Patients:
This phase III trial involved patients with extensive-stage small cell lung cancer (E-SCLC) that had not received previous therapy. Patients were divided into 2 separate treatment groups. Group 1 consisted of 324 patients with a median age of 62 years and 58% male. Group 2 had 327 patients with a median age of 63 years and 56% were male.

Treatment:
Patients in group 1 were treated with the chemotherapeutic agents irinotecan and cisplatin.

Patients in group 2 were administered chemotherapeutic agents etoposide and cisplatin.

Toxicities:
There were 11 treatment-related deaths reported in group 1 and 8 in group 2. Other severe toxicities were grade 3 and 4 myelosuppression (low blood cell count), fatigue, and nausea.

Results:
Median overall survival for group 1 was 9.9 months and median progression-free survival was 5.8 months.

For group 2, the median overall survival was 9.1 months and the median progression-free survival was 5.2 months.

Correspondence: Dr. Primo N. Lara; email: [email protected]



Back